Patient-centric company Belong.life has developed an app designed to inform cancer research by offering a holistic view of the lives of people with cancer.
The pharmaceutical company and the digital therapeutics specialist are joining forces to help accelerate the expansion of various digital health solutions.
The drug company has renewed its arrangement with the artificial intelligence specialist, centered on using AI to improve understanding of the immune system.
The pharma firm has allied with the biotech to create a scalable data, analytics, and infrastructure platform to generate insights from healthcare biobanks.
The drug discovery firm will work with the Dean Felsher Laboratory, using the company’s transomics platform to discover therapies for untreatable cancers.
This month’s announcements include hiring, expansion, and acquisition news from companies like DFE Pharma, ClinOne, Novartis, LEGO, Benchling, and more.
Returning to an in-person format March 21-24, the industry event is bringing a range of networking, educational, and social programming to New York City.
The recent Outsourcing-Pharma webinar hosted a trio of industry experts highlighting challenges, opportunities, and innovations in the rare disease realm.
Ergomed, a global contract research organization, is partnering with Trialbee to improve patient recruitment at its new Rare Disease Innovation Center.
The AI-centered genomics company is joining with Don’t Forget Morgan, a group for patients with BPAN, to explore treatments for the neurodegenerative condition.
The pharmaceutical company’s Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a ‘state-of-the-art’ facility.
The CRO is helping out on a project exploring the effects of the virus in children; other members of the research team include experts from Duke University.
On February 23, five days ahead of the day of rare-disease awareness, OSP’s Rare and Orphan Diseases webinar will share insights from top industry experts.
This month’s list of announcements about technology, funding, and more includes Medable, Clarify Health, Thermo Fisher Scientific, and other key companies.
The institute and the research/support organization will collaborate on development of novel therapies aimed at treating the central nervous system disorder.
An expert from the institutional review board services company advises what trends to look for in the clinical trial industry over the course of coming months.
Cullinan Oncology has formed a strategic partnership with the Icahn School of Medicine at Mount Sinai to research and develop targeted therapies for cancer.
A leader from the artificial intelligence insights specialist talks discusses how the effective use of advanced analytics can lead to a number of benefits.
The oncology center’s Marie-Josée and Henry R. Kravis Cancer Ecosystems Project is intended to elevate the next generation of preclinical cancer research.
This month’s announcements include new hires, promotions, acquisitions, and other events from Saama, Javara, Firma, GlaxoSmithKline, and other companies.
During OSP’s exclusive February 23 webinar Rare and Orphan Diseases, leading expertswill lend their unique experience and expertise to the important topic.
On World Cancer Day, the Union for International Cancer Control is launching a three-year campaign with the goal to improve cancer care around the globe.
The Stoneygate and Kidney Research UK Alport Research Hub aims to accelerate research and develop treatments for Alport syndrome, a rare genetic disorder.
A representative from IQVIA discusses the particulars of the US agency’s new draft document and shares what it might mean for clinical trial data evaluation.
The CRO's work with La Jolla Institute for Immunology, centered on a unique mouse model, is intended to increase understanding of how the COVID-19 virus operates.
This month’s list of new technology, partnerships, and other announcements includes items from ObvioHealth, Datavant, HumanFirst, and other industry players.
The pharmaceutical company reports studies have demonstrated the main protease inhibitor of Paxlovid maintains in vitro efficiency against the variant.
The researchers, in studying how polyps morph into colorectal cancer, have set a path for improved surveillance of the disease, harnessing precision medicine.
According to the company’s 12th Annual Pharmaceutical Innovation Report, pharmaceutical R&D return on investment has climbed to its highest peak since 2014.
Performance Cell Manufacturing, a CDMO with a focus on manufacturing cell therapies, has been acquired by Great Point Partners and will now operate under the name Cellipont Bioservices.
A leader from the company discusses challenges in control labs and shares how a new solution aims to clear some key obstacles to greater effectiveness.
The collaboration will center on development of unique data sets, which could be used in helping promote better understanding of aspects of human health.
Joining with a noted research foundation, the group is aiming for earlier detection and treatment of the disease, which hits nearly 500K people annually.
This month’s news on mergers and acquisitions, hires, and other developments includes notable firms like Altasciences, Protocol First, WuXi STA, and more.
Clover Biopharmaceuticals, a clinical-stage biotech developing novel vaccines and biologic therapeutic candidates, has started construction on a new R&D Center in Zhangjiang Biotech and Pharmaceutical Industrial Base in Shanghai.
An AI expert discusses progress in the field, gaps in understanding, and how predictive modeling and other advanced analytical tools could be put to use.
A forward-looking report from company experts includes a breakdown of the top trends to watch for in pharmaceutical development and in healthcare overall.
It has been a pleasure for the OSP team to connect with a long list of fascinating industry minds and share the stories; here are a few of our favorites.
This month’s collaborations, tech partnerships, new facilities, and other happenings includes news from Flywheel, Medable, Veeva, and other organizations.
A leader from the R&D tech provider discusses the obstacles faced by drug development professionals in recent months, and ways they rose to the occasion.
The artificial intelligence-driven drug discovery company has dosed its first healthy volunteer in a trial for a candidate to treat idiopathic pulmonary fibrosis.
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
The healthcare company has gifted $1m to form a scholarship fund for students headed toward careers in clinical research, with the aim of increasing diversity.
A leader from the advanced data and artificial intelligence specialist suggests ways to advance data collection through new tools, techniques, and thinking.
Sited in Pennsylvania, the excipients specialist’s new facility reportedly will work toward advancing drug delivery research and boosting speed to market.
According to a leader from Cytoreason, AI isn’t necessarily the best or only tool suited to discover new and novel therapies—it might take a human touch.
This month’s announcements of awards, expansions, name changes, hires, and other news includes items from CPhI, Almac Group, ICON, and other organizations.
The biotech firm has presented data from a study that could offer hope to patients with Parkinson’s, Gaucher, Alzheimer’s and other neurodegenerative conditions.
A leader from Sema4, the health intelligence company, explains how progress in genetic testing has helped advance breast cancer detection and prevention.
A new clinical trial of heterologous – or ‘mix-and-match’ – combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.